L
LXEO
vs
S&P 500
S&P 500
Over the past 12 months, LXEO has significantly outperformed S&P 500, delivering a return of +52% compared to the S&P 500's +12% growth.
Stocks Performance
LXEO vs S&P 500
Performance Gap
LXEO vs S&P 500
Performance By Year
LXEO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lexeo Therapeutics Inc
Glance View
Lexeo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 53 full-time employees. The company went IPO on 2023-11-03. Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company. The firm has developed a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have unmet need and no approved treatments that address the underlying genetic cause of the disease. These programs include: LX2006, LX2020, LX2021, and LX2022. LX2006 is a gene therapy candidate designed to intravenously deliver a functional frataxin (FXN), a gene for the treatment of Friedreich’s ataxia (FA) cardiomyopathy. LX2020 is a gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the treatment of PKP2-ACM. LX2021 is a gene therapy candidate developing to intravenously deliver the coding sequence for the functional connexin 43 (Cx43) protein for a group of inherited cardiac muscle disorders. LX2022 delivers a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy (HCM).
